Literature DB >> 16078126

Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma.

Yuichiro Doki1, Osamu Ishikawa, Ko Takachi, Isao Miyashiro, Yo Sasaki, Hiroaki Ohigashi, Kohei Murata, Terumasa Yamada, Shingo Noura, Hidetoshi Eguchi, Toshiyuki Kabuto, Shingi Imaoka.   

Abstract

The site of surgical failure in cases of thoracic esophageal cancer (TEC) may be affected by the vertical location of the cancer in this longitudinal organ, suggesting the need to select the mode of adjuvant therapy based on location. We classified 501 TECs (92% squamous cell carcinomas) that underwent curative surgery without preoperative treatment as 13% upper thoracic (Ut), 51% middle thoracic (Mt), and 36% lower thoracic (Lt) lesions. Recurrent disease was discovered in 180 (36%) of the patients during a postoperative survey, most frequently in the cervical nodes (19%), liver (18%), abdominal paraaortic nodes (17%), and upper mediastinal nodes (17%). Although postoperative survival rates were similar (5-year survival: Ut 51%, Mt 55%, Lt 54%), the tumor recurrence site was significantly affected by the TEC vertical location, with recurrence in the cervical and upper mediastinal nodes being most frequent for Ut and Mt cases and in the liver and abdominal paraaortic nodes for Lt cases. Insufficient surgical lymph node clearance could be assessed by the recurrence index (RI), defined as the frequency of metastasis at recurrence divided by that at surgery. The RI was significantly lower for the upper abdominal nodes (4%, 8/184) than the lower mediastinal nodes (15%, 19/123) or the upper mediastinal nodes (19%, 30/154). These findings indicated that regional tumor recurrence, corresponding to the surgical field, was more frequent in the Ut and Mt cases (53% and 51%) than the Lt cases (18%); and distant recurrence was more frequent in the Lt cases (62%) than in Ut or Mt cases (25% and 36%). Thus the vertical location of the thoracic esophageal cancer can be said to affected strongly the site of tumor recurrence after curative surgery. Regional radiotherapy might be expected to have an adjuvant effect on Ut/Mt tumors and systemic chemotherapy on Lt tumors.

Entities:  

Mesh:

Year:  2005        PMID: 16078126     DOI: 10.1007/s00268-005-7596-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  Significance of extended systemic lymph node dissection for thoracic esophageal carcinoma in Japan.

Authors:  H Watanabe; H Kato; Y Tachimori
Journal:  Recent Results Cancer Res       Date:  2000

Review 2.  Two-field dissection is enough for esophageal cancer.

Authors:  S Law; J Wong
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

3.  Predicting initial recurrence pattern of esophageal cancer after neoadjuvant chemotherapy.

Authors:  Y Tabira; M Yasunaga; T Sakaguchi; N Nagamoto; S Ogi; N Kitamura
Journal:  Hepatogastroenterology       Date:  2000 Sep-Oct

4.  Does pleural lavage cytology before thoracic closure predict both patient's prognosis and site of cancer recurrence after resection of esophageal cancer?

Authors:  Y Doki; T Kabuto; O Ishikawa; H Ohigashi; Y Sasaki; T Yamada; M Hiratsuka; I Miyashiro; M Kameyama; K Murata; S Imaoka; T Yasuda; A Nakaizumi; A Takenaka
Journal:  Surgery       Date:  2001-11       Impact factor: 3.982

5.  Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus.

Authors:  T Matsubara; M Ueda; T Takahashi; T Nakajima; M Nishi
Journal:  J Am Coll Surg       Date:  1996-04       Impact factor: 6.113

6.  Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer.

Authors:  H Shiozaki; M Yano; T Tsujinaka; M Inoue; S Tamura; Y Doki; T Yasuda; Y Fujiwara; M Monden
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

7.  Radical lymph node dissection for cancer of the thoracic esophagus.

Authors:  H Akiyama; M Tsurumaru; H Udagawa; Y Kajiyama
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

Review 8.  Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future.

Authors:  Lawrence Leichman; Lakshmi Pendyala; Cynthia Gail Leichman
Journal:  Semin Oncol       Date:  2003-08       Impact factor: 4.929

9.  [Experimental and clinical study on the lymphatic pathway draining from the distal esophagus and gastric cardia].

Authors:  S Natsugoe
Journal:  Nihon Geka Gakkai Zasshi       Date:  1989-03

10.  Pattern of recurrence after extended esophagectomy for squamous cell carcinoma of the esophagus.

Authors:  Ioannis D Kyriazanos; Mitsuo Tachibana; Muneaki Shibakita; Hiroshi Yoshimura; Shoichi Kinugasa; Dipok K Dhar; Takeru Nakamoto; Toshiyuki Fujii; Naofumi Nagasue
Journal:  Hepatogastroenterology       Date:  2003 Jan-Feb
View more
  23 in total

1.  Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection.

Authors:  Po-Kuei Hsu; Bing-Yen Wang; Chien-Sheng Huang; Yu-Chung Wu; Wen-Hu Hsu
Journal:  J Gastrointest Surg       Date:  2011-02-15       Impact factor: 3.452

2.  Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.

Authors:  Jia Wang; Nan Wu; Qing-Feng Zheng; Shi Yan; Chao Lv; Shao-Lei Li; Yue Yang
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

3.  Patterns and time of recurrence after complete resection of esophageal cancer.

Authors:  Masahiko Sugiyama; Masaru Morita; Rintaro Yoshida; Koji Ando; Akinori Egashira; Ohga Takefumi; Hiroshi Saeki; Eiji Oki; Yoshihiro Kakeji; Yoshihisa Sakaguchi; Yoshihiko Maehara
Journal:  Surg Today       Date:  2012-02-28       Impact factor: 2.549

4.  [Lymphadenectomy with tumors of the upper gastrointestinal tract].

Authors:  C Schuhmacher; A Novotny; K Ott; M Feith; J R Siewert
Journal:  Chirurg       Date:  2007-03       Impact factor: 0.955

5.  Preliminary evaluation of postoperative radiotherapy with small T-shaped field in thoracic esophageal squamous cell carcinoma.

Authors:  Qi Zhao; Jiaxing Zhu; Yandong Liu; Songbing Qin; Juying Zhou
Journal:  J Gastrointest Oncol       Date:  2021-10

6.  Patterns and Outcomes of Recurrent Esophageal Cancer After Curative Esophagectomy.

Authors:  Kotaro Yamashita; Masayuki Watanabe; Shinji Mine; Takanori Kurogochi; Akihiko Okamura; Masaru Hayami; Yu Imamura
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

7.  Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma.

Authors:  K Fakhrian; M Oechsner; S Kampfer; T Schuster; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

8.  Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.

Authors:  Baoqing Chen; Qiwen Li; Qiaoqiao Li; Bo Qiu; Mian Xi; Mengzhong Liu; Yonghong Hu; Yujia Zhu
Journal:  Oncologist       Date:  2019-12-27

9.  Efficacy of intraoperative radiotherapy targeted to the abdominal lymph node area in patients with esophageal carcinoma.

Authors:  Yukihisa Tamaki; Ryohei Sasaki; Yasuo Ejima; Masakazu Ogura; Yoshiharu Negoro; Toshifumi Nakajima; Masao Murakami; Yasushi Kaji; Kazuro Sugimura
Journal:  J Radiat Res       Date:  2012-08-07       Impact factor: 2.724

10.  Arterial Infusion Chemotherapy for Neoplastic Esophagogastric Anastomotic Strictures After Esophagectomy.

Authors:  Pengfei Xie; Meipan Yin; Wei He; Yaozhen Ma; Chunxia Li; Zhen Li; Xiaobing Li; Shuai Wang; Gang Wu
Journal:  Front Oncol       Date:  2021-05-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.